Skip to main content
Acta Crystallographica Section F: Structural Biology and Crystallization Communications logoLink to Acta Crystallographica Section F: Structural Biology and Crystallization Communications
. 2013 Mar 28;69(Pt 4):441–444. doi: 10.1107/S1744309113005745

Cloning, expression, purification, crystallization and preliminary crystallographic analysis of the N-terminal domain of serine glutamate repeat A (SgrA) protein from Enterococcus faecium

Revathi Nagarajan a, Antoni P A Hendrickx b,, Karthe Ponnuraj a,*
PMCID: PMC3614174  PMID: 23545655

The putative ligand-binding region of serine glutamate repeat A (SgrA) protein from E. faecium was overexpressed, purified and crystallized, and its preliminary X-ray diffraction analysis is reported at 3.3 Å resolution.

Keywords: surface adhesin, Enterococcus faecium, LPxTG surface protein, extracellular matrix

Abstract

Serine glutamate repeat A (SgrA) protein is an LPxTG surface adhesin of Enterococcus faecium and is the first bacterial nidogen-binding protein identified to date. It has been suggested that it binds to human nidogen, the extracellular matrix molecule of basal lamina, and plays a key role in the invasion and colonization of eukaryotic host cells. SgrA28–288, having both a putative ligand-binding A domain and repetitive B domain, was expressed in Escherichia coli and purified using Ni-affinity and hydrophobic interaction chromatography. Further, the putative ligand-binding region, rSgrA28–153, was subcloned, overexpressed and purified in both native and selenomethionine-derivative forms. The native rSgrA28–153 protein crystallized in the monoclinic space group P21 and diffracted to 3.3 Å resolution using an in-house X-ray source, with unit-cell parameters a = 35.84, b = 56.35, c = 60.20 Å, β = 106.5°.

1. Introduction  

Enterococci are Gram-positive facultatively anaerobic oval cocci and are commensals of the gastrointestinal tract of humans and other animals as well as those of insects and nematodes (Murray, 1990). During the last three decades, Enterococcus faecium has emerged as an opportunistic pathogen and is a common cause of nosocomial infections such as septicaemia, endocarditis and urinary-tract infections in immunocompromised patients (Richards et al., 2000). The hospital-associated E. faecium strains are highly resistant to ampicillin, ciprofloxacin and vancomycin (Arias & Murray, 2012) and are enriched in LPxTG-type surface proteins (Hendrickx et al., 2007). The treatment of enterococcal infections has become challenging as resistance to newly developed antibiotics has been observed (Hendrickx, Luit-Asbroek et al., 2009).

It has been proposed that several enterococcal genes, including those encoding cell-wall-anchored LPxTG-type surface proteins, are involved in the pathogenesis of enterococcal infections (Hendrickx, Luit-Asbroek et al., 2009; Hendrickx, Willems et al., 2009). Adherence is the critical first step in bacterial pathogenesis or infection. Most pathogenic bacteria have been shown to recognize and adhere to various components of extracellular matrix (ECM), leading to colonization of the host tissue (Patti & Höök, 1994; Foster & Höök, 1998; Murray, 2000). ECM includes glycoproteins such as collagen, fibrin­ogen, fibronectin, nidogen and laminin, the latter two forming the underlying basement membrane of epithelial and endothelial cells (Hay, 1991).

Serine glutamate repeat A (SgrA) is an LPxTG surface adhesin of E. faecium. It consists of 324 amino acids and is a marker of multi-drug-resistant and hospital-associated E. faecium. It has an N-terminal signal peptide, a nonrepetitive A domain, a repetitive B domain containing eight repeats of Ser–Ser–Glu–Ser–Ser–Thr followed by a cell-wall sorting signal (CWS), which is composed of highly conserved LPxTG-like (Leu–Pro–x–Thr–Gly, where x denotes any amino acid) sortase substrate motif, a hydrophobic domain and a short C-terminal charged tail (Hendrickx, Willems et al., 2009; Fig. 1). After trans­location of the precursor protein, the LPxTG motif is cleaved by a housekeeping sortase, which subsequently anchors the surface protein to the cell-wall peptidoglycan. SgrA is thought to bind to protein ligands of ECM especially fibrinogen and nidogen (Hendrickx, Luit-Asbroek et al., 2009). Fibrinogen is a large 340 kDa plasma protein and plays an important role in homeostasis and coagulation. The two homologous proteins nidogen-1 (entactin) and nidogen-2 are sulfated monomeric glycoproteins of 150 and 200 kDa, respectively. Nidogens are found ubiquitously in basement membranes. Previous study reveals that rSgrA28–288 binds to α and β chains of fibrinogen and to nidogen (Hendrickx, Luit-Asbroek et al., 2009). The N-terminal region of SgrA (A domain, residues 28–153) is considered to be the putative ligand-binding domain (Hendrickx, Luit-Asbroek et al., 2009).

Figure 1.

Figure 1

Structural organization of the SgrA surface protein of E. faecium. The signal peptide, cell-wall anchoring domain, membrane-spanning domain and positively charged C-terminal domain are indicated by S, W, M and C, respectively. The nonrepetitive ligand-binding region followed by the repeat region is shown.

Enterococci have been associated with the formation of biofilms on various kinds of in-dwelling medical devices, such as artificial hip prostheses, intra-uterine devices, prosthetic heart valves, central venous catheters and urinary catheters, leading to many infections (Donlan, 2002; Paganelli et al., 2012). Previously, it was shown that SgrA mediates biofilm formation onto a polystyrene abiotic surface but not onto biotic surfaces such as human intestinal epithelial cells, human bladder cells and kidney cells (Hendrickx, Luit-Asbroek et al., 2009). This suggests that SgrA may also play a role in adhesion to medical-device-related infections by forming a biofilm.

Here, we report the cloning, expression, purification, crystallization and preliminary X-ray analysis of the ligand-binding region of recombinant SgrA (rSgrA28–153). Understanding the structure of rSgrA28–153 and subsequent biochemical studies with human nidogen and fibrinogen will be useful in the development of novel thera­peutics against enterococcal infections.

2. Materials and methods  

2.1. Cloning and expression of rSgrA28–288 and rSgrA28–153  

The DNA sequence encoding both the A and B regions of SgrA (residues 28–288; molecular mass 31 kDa) was amplified by polymerase chain reaction (PCR) from genomic DNA of E. faecium TX0016. To generate a C-terminally His6-tagged fusion protein, the PCR product was cloned into a BamHI/XhoI-digested expression vector pET-24b(+). The resulting plasmid was transformed into the expression host Escherichia coli BL21(DE3) and protein expression was carried out in Luria–Bertani (LB) medium. A 10 ml overnight culture was prepared and transferred to 1 l LB medium supplemented with 50 µg ml−1 kanamycin and allowed to grow at 310 K with shaking (180 rev min−1) until an optimum optical density (OD600 of 0.5–0.6) was reached. At this point, expression of the recombinant protein was induced with 1 mM isopropyl β-d-1-thiogalactopyranoside (IPTG) at 310 K. After 5 h of incubation with shaking, bacterial cells were harvested by centrifugation at 4000 rev min−1 for 20 min at 277 K.

The primers 5′-CGC GGA TCC AAT GAA CGG GCA AAT GAG AAT-3′ and 5′-CGG CTC GAG GCT ATC CGT ACT GCT TGG-3′ were designed for PCR amplification of sgrA segment 28–153. The BamHI and XhoI restriction sites in the forward and reverse primers, respectively, are shown in bold. The plasmid DNA encoding the full-length recombinant sgrA gene (both A and B regions) in the pET-24b(+) vector was used as a template. After digestion with BamHI and XhoI restriction enzymes, the PCR product was cloned into the expression vector pET-28a(+). The construct was confirmed by DNA sequencing and allows expression of the protein with both N and C-terminal 6×His tags.

E. coli BL21 (DE3) cells were transformed with the plasmid pET-28a(+)-sgrA28–153 and grown on LB agar plates containing 50 µg ml−1 kanamycin. Following overnight incubation at 310 K, single colonies were transferred into 10 ml LB broth containing 50 µg ml−1 kanamycin and grown overnight at 310 K with shaking (180 rev min−1). The cells were diluted 1/100 in flasks containing 1 l LB broth supplemented with 50 µg ml−1 kanamycin and cultivated at 310 K with continuous shaking (180 rev min−1) until an OD600nm of 0.6 was reached. The cells were subsequently treated with 1 mM IPTG to induce the expression of recombinant SgrA A domain (rSgrA28–153). After 5 h of incubation with continuous shaking (180 rev min−1) at 310 K, the cells were harvested by centrifugation at 4000 rev min−1 for 20 min at 277 K.

2.2. Purification of full-length SgrA (rSgrA28–288)  

The cell pellet was resuspended in 25 ml cold lysis buffer (20 mM Tris–HCl pH 6.5, 500 mM NaCl, 0.01% Triton X-100, 5% glycerol) with 1 mM phenylmethanesulfonyl fluoride (PMSF) and ultrasonicated for 2 min with 25% amplitude (20 s on, 10 s off) on ice. This lysate solution was spun down at 10 000 rev min−1 for 45 min at 277 K. The supernatant and pellet were analysed on a 15% SDS–PAGE gel and the protein was detected in the soluble fraction. The supernatant was passed through a 0.22 µm membrane filter to remove any cell debris in preparation for protein purification. The first step involved in protein purification was immobilized metal-affinity chromatography (IMAC) using an Ni–NTA column (5 ml HisTrap column, GE Healthcare) which was equilibrated in lysis buffer to capture the target 6×His-tagged fusion protein from the supernatant. The bound protein was eluted using a linear gradient of 0–1 M imidazole in the lysis buffer. The fractions containing target protein were verified on 15% SDS–PAGE, pooled, concentrated to approximately 2 ml and then subjected to ammonium sulfate precipitation. In an initial analysis it was found that the protein remains soluble up to 1.5 M ammonium sulfate and precipitates at 2 M. Hence, the protein was precipitated with 2 M ammonium sulfate and the pellet was resuspended in 2 ml lysis buffer containing 1.5 M ammonium sulfate. This solution was centrifuged at 10 000 rev min−1 for 10 min at 277 K. The supernatant containing protein was filtered and loaded onto a pre-equilibrated Phenyl Sepharose HP column (GE Healthcare). The protein was eluted using a gradient of 1.5–0.0 M ammonium sulfate in lysis buffer. The peak fractions were verified on 15% SDS–PAGE and pure fractions were pooled and dialysed overnight against buffer consisting of 20 mM Tris–HCl pH 6.5, 200 mM NaCl, 0.01% Triton X-100, 5% glycerol to remove excess sodium chloride and ammonium sulfate. The purified protein was concentrated to 500 µl and the concentration of the protein was measured using a UV spectrophotometer (A280) and assuming a calculated absorption coefficient of 0.772 (ProtParam; Gasteiger et al., 2005) with a final yield of 40 mg ml−1 per litre of culture. Crystallization trials were carried out with an initial concentration of 25 mg ml−1.

2.3. Purification of the A domain of SgrA (rSgrA28–153)  

For purifying rSgrA28–153, a similar purification protocol to that used for rSgrA28–288 was carried out with slight changes in the buffer condition. In brief, buffer A consisting of 20 mM Tris–HCl pH 7.5, 500 mM NaCl, 0.01% Triton X-100, 5% glycerol was used for IMAC and hydrophobic interaction chromatography (HIC). It was found that rSgrA28–153 precipitates at 1 M ammonium sulfate and is soluble at 0.5 M ammonium sulfate. The fractions containing target protein obtained from the IMAC column were subjected to a Phenyl Sepharose HP column pre-equilibrated with buffer A containing 0.5 M ammonium sulfate. The bound protein was eluted with a linear gradient of 0.5–0.0 M ammonium sulfate in buffer A. The peak fractions were analysed on 15% SDS–PAGE and pure fractions were pooled and dialysed overnight against buffer A to remove ammonium sulfate. The concentration of rSgrA28–153 was measured using a UV spectrophotometer (A280) assuming a calculated absorption coefficient of 1.49 (ProtParam; Gasteiger et al., 2005). A final yield of 6 mg protein was obtained from a 500 ml culture and was used for crystallization trials.

2.4. Crystallization of rSgrA28–288 and rSgrA28–153  

Crystallization experiments were carried out using the hanging-drop vapour-diffusion method with Hampton Research screens (Crystal Screen, Crystal Screen 2, PEG/Ion, PEG/Ion 2 and SaltRx) and home-made screens such as ammonium sulfate versus pH and polyethylene glycol versus pH for both the rSgrA28–288 and the rSgrA28–153 proteins. Extensive crystallization trials were carried out for both rSgrA28–288 and rSgrA28–153. However, rSgrA28–288 did not yield any crystals. In the case of rSgrA28–153 thin needle-like crystals were obtained with PEG 2000 monomethyl ether (PEG 2K MME) as a precipitant.

2.5. Data collection and processing  

For X-ray data collection, native rSgrA28–153 crystals were soaked for 30 s in reservoir solution supplemented with 20% glycerol and flash-cooled in a nitrogen-gas stream at 100 K. Diffraction data were collected at our in-house data-collection facility using a MAR345 image-plate detector and a Bruker Microstar copper rotating-anode generator operating at 60 mA and 45 kV. A total of 180 frames were collected with an oscillation step of 1° and an exposure of 180 s per frame. The crystal-to-detector distance was maintained at 150 mm. The diffraction data were processed and scaled using iMOSFLM (Battye et al., 2011). The crystal parameters and data-collection statistics are summarized in Table 1.

Table 1. Data-collection statistics.

Values in parentheses are for the highest-resolution shell.

Wavelength (Å) 1.5418
Space group P21
Unit-cell parameters (Å, °) a = 35.84, b = 56.35, c = 60.20, β = 106.5
Resolution range (Å) 30.00–3.3 (3.42–3.30)
R merge (%) 12.4 (22.1)
Total no. of reflections 12056
No. of unique reflections 3530
Mean I/σ(I) 4.2 (1.9)
Completeness (%) 98.9 (95.0)
Multiplicity 3.3

R merge = Inline graphic Inline graphic.

2.6. Preparation of selenomethionine derivative of rSgrA28–153  

rSgrA28–153 contains four methionine residues. A selenomethionine derivative was prepared by growing cells with pET-28a(+)-sgrA28–153 plasmid in 1× M9 minimal medium (Sambrook et al., 1989) supplemented with 50 µg ml−1 kanamycin. The incorporation of selenomethionine was carried out using the methionine-auxotroph strain of E. coli B834. For this, the pET-28a(+)/sgrA28–153 gene construct was transformed into competent B834 strain and expression was performed in 1× M9 minimal medium. SeMet-rSgrA28–153 was prepared in the following way: 10 ml LB medium supplemented with 50 µg ml−1 kanamycin was inoculated with B834 harbouring pET-28a(+)/sgrA. The overnight-grown culture was spun down at 4000 rev min−1 for 10 min, resuspended in 10 ml 1× M9 minimal medium and transferred to 1 l of 1× M9 minimal medium supplemented with kanamycin. After 1 h, 40 mg of selenomethionine was added to the 1 l culture. The culture was grown for an additional 9 h followed by overnight induction with 1 mM IPTG. Following this, harvesting the cells and purification of the protein were carried out in the same way as for the native protein. However, 5 mM β-mercaptoethanol was added to the buffer to avoid the oxidation of selenomethionine.

3. Results and discussion  

The rSgrA28–288 protein consists of two regions: the N-terminal putative ligand-binding A domain and the C-terminal repetitive B domain. To facilitate purification, the rSgrA28–288 protein was expressed with an LEHHHHHH motif at its C-terminus. The purity of rSgrA28–288 used in the crystallization experiments was checked by 15% SDS–PAGE analysis and the 31 kDa protein migrated at around 43 kDa (Fig. 2). Also, multiple bands were observed below the 43 kDa band, indicating that the protein is likely to be degraded or unstable. A similar degradation pattern was observed in a family of Group B Streptococcal surface proteins of repetitive nature, namely Alpha-C and Rib (Wästfelt et al., 1996), and recently in FbsA, the fibrinogen-binding protein (Ponnuraj & Ragunathan, 2011). Thus, in rSgrA28–288 the presence of the C-terminal repetitive B domain which consists of eight repeats of a Ser–Ser–Glu–Ser–Ser–Thr motif could be the reason for instability of the protein and its failure to crystallize.

Figure 2.

Figure 2

SDS–PAGE of purified rSgrA28–288 and rSgrA28–153. Lane 1, molecular-weight marker (labelled in kDa); lane 2, final purified rSgrA28–288 (10 mg ml−1); lane 3, rSgrA28–153 (8 mg ml−1). 10 µl of protein mixed with 5 µl of loading dye was loaded in lanes 2 and 3.

In an attempt to crystallize the ligand-binding A domain (devoid of the B repeat region), rSgrA28–153 was cloned and expressed in E. coli BL21 (DE3) cells. The PCR-amplified sgrA segment 28–153 was inserted into the pET28a vector using its BamHI and XhoI sites. The sequence upstream of the BamHI site encodes a 6×His tag followed by additional residues which include a thrombin cleavage site. The sequence downstream of the XhoI site encodes another 6×His tag followed by a stop codon. Thus, the rSgrA28–153 construct contains 126 residues of SgrA plus 42 residues [34 residues at the N-terminus (MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGS) and eight residues (LEHHHHHH) at the C-terminus] from the cloning vector. These tags were not removed prior to crystallization. Mass spectrometry confirmed the molecular mass of 20 kDa and the protein was found to migrate at around 25 kDa in 15% SDS–PAGE (Fig. 2). The protein was purified to homogeneity and screened for crystallization.

Initial crystals of rSgrA28–153 appeared after 3 months using PEG 2K MME as a precipitant. Various optimization procedures such as the addition of reducing agents and salts to the reservoir solution and microseeding were tried in order to obtain diffraction-quality crystals. Finally, a drop consisting of 1 µl protein solution and 1 µl reservoir solution (40% PEG 2K MME, 100 mM HEPES pH 7.5) seeded with microseeds gave crystals that were suitable for data collection (Fig. 3). The drop was equilibrated against 1 ml reservoir solution and crystals were obtained in 2 d. A native data set was collected from a single crystal to a resolution of 3.3 Å. The crystal lattice was primitive monoclinic, with unit-cell parameters a = 35.84, b = 56.35, c = 60.20 Å, β = 106.5°, and the space group was deduced to be P21. The values for the crystal volume per unit protein mass (V M, Matthews coefficient) and solvent content were computed to be 2.94 Å3 Da−1 and 58.14%, respectively, which correspond to one molecule per asymmetric unit. Alternatively, if there are two molecules in the asymmetric unit, the values are 1.47 Å3 Da−1 and 16.35%, respectively (Matthews, 1968).

Figure 3.

Figure 3

Thin needle-like crystals of rSgrA28–153 of E. faecium.

Based on the crystallization experiments of the rSgrA28–288 and rSgrA28–153 proteins it is evident that although both proteins were expressed with identical tags on their C-termini, the crystals were only obtained with rSgrA28–153, which also has an N-terminal His tag. In the longer construct, rSgrA28–288, the His tag is probably not intact because it was fused with the repetitive B domain which is likely to be unstable. Thus, the rSgrA28–288 sample used for crystallization might contain different molecular species of rSgrA28–288, each with a different number of B repeats. The protein heterogeneity, as observed by a laddering pattern in SDS–PAGE (Fig. 2), could be the reason for the failure of rSgrA28–288 to crystallize even after several rounds of purification and crystallization trials with various protein concentrations.

The crystallized construct rSgrA28–153 does not have a homologous structure in the PDB and therefore determination of its structure by molecular replacement is not possible. It contains four methionine residues which can be modified to selenomethionine (SeMet) in order to resolve the phase problem using the multi-wavelength anomalous dispersion (MAD) or single-wavelength anomalous dispersion (SAD) techniques. The SeMet-substituted protein was prepared using a methionine-auxotroph strain in minimal medium (M9 medium) as described in §2.6. Crystals of SeMet-substituted rSgrA28–153 were obtained under similar conditions to those used for the native protein, but were not of diffraction quality. However, the incorporation of selenomethionine into the crystal was detected using X-ray fluorescence spectroscopy at the synchrotron beamline. Further crystallization trials are under way in order to obtain diffraction-quality crystals of SeMet-incorporated rSgrA28–153. A three-wavelength MAD data set or a single-wavelength SAD data set will be collected to solve the structure of the protein. If diffraction-quality SeMet-rSgrA28–153 crystals are not obtained, halide-ion soaking and xenon derivatization will be attempted with native crystals to solve the phase problem. If these methods also fail, nuclear magnetic resonance (NMR) will be attempted to obtain a solution structure of rSgrA28–153.

Acknowledgments

KP thanks the Department of Biotechnology (DBT), Government of India, for financial support in the form of a grant. RN thanks the University Grants Commission (UGC), India, for providing a fellowship.

References

  1. Arias, C. A. & Murray, B. E. (2012). Nature Rev. Microbiol. 16, 266–278. [DOI] [PMC free article] [PubMed]
  2. Battye, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R. & Leslie, A. G. W. (2011). Acta Cryst. D67, 271–281. [DOI] [PMC free article] [PubMed]
  3. Donlan, R. M. (2002). Emerg. Infect. Dis. 8, 881–890. [DOI] [PMC free article] [PubMed]
  4. Foster, T. J. & Höök, M. (1998). Trends Microbiol. 6, 484–488. [DOI] [PubMed]
  5. Gasteiger, E., Hoogland, C., Gattiker, A., Duvaud, S., Wilkins, M. R., Appel, R. D. & Bairoch, A. (2005). The Proteomics Protocols Handbook, edited by J. M. Walker, pp. 571–607. Totowa: Humana Press.
  6. Hay, E. D. (1991). Cell Biology of Extracellular Matrix. New York: Plenum Press.
  7. Hendrickx, A. P. A., van Luit-Asbroek, M. V., Schapendonk, C. M. E., van Wamel, W. J. B., Braat, J. C., Wijiands, L. C., Bonten, M. J. M. & Willems, R. J. L. (2009). Infect. Immun. 77, 5097–5106. [DOI] [PMC free article] [PubMed]
  8. Hendrickx, A. P. A., van Wamel, W. J. B., Posthuma, G., Bonten, M. J. M. & Willems, R. J. L. (2007). J. Bacteriol. 189, 8321–8332. [DOI] [PMC free article] [PubMed]
  9. Hendrickx, A. P. A., Willems, R. J. L., Bonten, M. J. M. & van Schaik, W. (2009). Trends Microbiol. 17, 423–430. [DOI] [PubMed]
  10. Matthews, B. W. (1968). J. Mol. Biol. 33, 491–497. [DOI] [PubMed]
  11. Murray, B. E. (1990). Clin. Microbiol. Rev. 3, 46–65. [DOI] [PMC free article] [PubMed]
  12. Murray, B. E. (2000). N. Engl. J. Med. 342, 710–721. [DOI] [PubMed]
  13. Paganelli, F. L., Willems, R. J. & Leavis, H. L. (2012). Trends Microbiol. 20, 40–49. [DOI] [PubMed]
  14. Patti, J. M. & Höök, M. (1994). Curr. Opin. Cell Biol. 6, 752–758. [DOI] [PubMed]
  15. Ponnuraj, K. & Ragunathan, P. (2011). Protein J. 30, 159–166. [DOI] [PubMed]
  16. Richards, M. J., Edwards, J. R., Culver, D. H. & Gaynes, R. P. (2000). Infect. Control Hosp. Epidemiol. 21, 510–515. [DOI] [PubMed]
  17. Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989). Molecular Cloning: a Laboratory Manual. New York: Cold Spring Harbor Laboratory Press.
  18. Wästfelt, M., Stâlhammar-Carlemalm, M., Delisse, A. M., Cabezon, T. & Lindahl, G. (1996). J. Biol. Chem. 271, 18892–18897. [DOI] [PubMed]

Articles from Acta Crystallographica Section F: Structural Biology and Crystallization Communications are provided here courtesy of International Union of Crystallography

RESOURCES